多体与1p/19q共缺失少突胶质细胞肿瘤的不良预后相关
该研究分析了1996至2013年间8家机构412例经1p/19q检测的组织学少突胶质细胞肿瘤,采用FISH检测1p/19q,多体定义为细胞中1q和19p信号超过两个。结果显示,1p/19q缺失组中合并多体者无进展生存期显著短于单纯共缺失者(P<0.0001),但多体在1p/19q保留组中无预后意义。
要点
- 1p/19q共缺失的少突胶质细胞肿瘤中,合并多体提示早期复发和生存期缩短。
- 多体在1p/19q保留的肿瘤中未见预后价值。
- 多体细胞比例>30%与<30%之间生存无差异。
核心结论
- 1p/19q共缺失的少突胶质细胞肿瘤若存在多体,则预测早期复发和较短生存。
研究设计与样本
- 回顾性分析1996至2013年8家机构412例组织学少突胶质细胞肿瘤,均行1p/19q FISH检测。
主要发现
- 412例中333例(81%)有1p/19q缺失,其中195例(59%)合并多体,138例(41%)无多体。
- 79例(19%)1p/19q保留,其中30例(38%)合并多体,49例(62%)无多体。
- 1p/19q缺失组无进展生存期和总生存期均显著优于1p/19q保留组(P<0.0001)。
- 1p/19q缺失合并多体者无进展生存期显著短于单纯1p/19q共缺失者(P<0.0001)。
- 1p/19q缺失合并多体者无进展生存期和总生存期均长于1p/19q保留组(P<0.01和P<0.0001)。
关键数值与推荐
- 多体定义为细胞中1q和19p信号超过两个。
- 多体细胞比例>30%与<30%之间生存无差异。
- 多体在1p/19q保留患者中对无进展生存期或总生存期无预后意义。
临床怎么用
- 对1p/19q共缺失的少突胶质细胞肿瘤,应评估多体以识别早期复发高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chromosomal instability is associated with earlier progression in isocitrate dehydrogenase (IDH)-mutated astrocytomas. Here we evaluated the prognostic significance of polysomy in gliomas tested for 1p/19q status. METHODS: We analyzed 412 histologic oligodendroglial tumors with use of 1p/19q testing at 8 institutions from 1996 to 2013; fluorescence in situ hybridization (FISH) for 1p/19q was performed. Polysomy was defined as more than two 1q and 19p signals in cells. Tumors were divided into groups on the basis of their 1p/19q status and polysomy and were compared for progression-free survival (PFS) and overall survival (OS). RESULTS: In our cohort, 333 tumors (81%) had 1p/19q loss; of these, 195 (59%) had concurrent polysomy and 138 (41%) lacked polysomy, 79 (19%) had 1p/19q maintenance; of these, 30 (38%) had concurrent polysomy and 49 (62%) lacked polysomy. In agreement with prior studies, the group with 1p/19q loss had significantly better PFS and OS than did the group with 1p/19q maintenance (P < 0.0001 each). Patients with 1p/19q loss and polysomy showed significantly shorter PFS survival than patients with 1p/19q codeletion only (P < 0.0001), but longer PFS and OS than patients with 1p/19q maintenance (P < 0.01 and P < 0.0001). There was no difference in survival between tumors with >30% polysomic cells and those with <30% polysomic cells. Polysomy had no prognostic significance on PFS or OS in patients with 1p/19q maintenance. CONCLUSIONS: The presence of polysomy in oligodendroglial tumors with codeletion of 1p/19q predicts early recurrence and short survival in patients with 1p/19q codeleted tumors.
引用
- Chen H, Thomas C, Munoz FA, et al. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro Oncol. 2019. PMID: 31140557. doi:10.1093/neuonc/noz098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。